

REMARKS

Applicant respectfully requests reconsideration of the claims. Claims 1, 4, 12, 34 and 38-41 were previously pending in this application. Claims 1, 4, 40 and 41 are allowed. Claims 12, 38 and 39 are objected to. Claim 34 is rejected.

Claims 1, 4, 12 and 34 have been amended. Claims 38 and 39 have been canceled. As a result, claims 1, 4, 12, 34, 40 and 41 are pending for examination with claims 1, 4, 12, 40 and 41 being independent claims.

Claims 4 and 12 have been made independent claims, and the subject matter of claims 38 and 39 has been added to claims 1 and 4, respectively, to overcome the objection to the claims as to form.

Claim 34 has been amended in order to expedite prosecution by clarifying that the composition comprises an isolated polypeptide as claimed in claim 12.

No new matter has been added.

Objections to the Specification

The Examiner objected to the specification as containing hyperlinked text and as lacking sequence identifiers for certain sequence recitations. Applicant has amended the specification to remove the hyperlinks and to provide the required sequence identifiers. Accordingly, Applicant respectfully requests reconsideration and withdrawal of the objections.

Objections to the Claims

The Examiner objected to claims 12, 34, 38 and 39 as being of improper dependent form. Applicant has amended or canceled these claims to provide independent claims or claims of proper dependent form. Accordingly, Applicant respectfully requests reconsideration and withdrawal of the objections.

Rejections Under 35 U.S.C. § 112

The Examiner rejected claim 34 under 35 U.S.C. § 112, first paragraph, as not enabled by the specification. Applicant has amended the claim and respectfully requests reconsideration of the rejection.

The Examiner indicated that claim 34 was enabled for pharmaceutical compositions comprising a polypeptide of SEQ ID NO:30. Applicant has amended claim 34 to remove subject matter relating to other types of pharmaceutical compositions, leaving only pharmaceutical compositions comprising a polypeptide of SEQ ID NO:30.

Accordingly, withdrawal of the rejection of claim 34 under 35 U.S.C. § 112 is respectfully requested.


CONCLUSION

A Notice of Allowance is respectfully requested. The Examiner is requested to call the undersigned at the telephone number listed below if this communication does not place the case in condition for allowance.

If this response is not considered timely filed and if a request for an extension of time is otherwise absent, Applicant hereby requests any necessary extension of time. If there is a fee occasioned by this response, including an extension fee, that is not covered by an enclosed check, please charge any deficiency to Deposit Account No. 23/2825.

Respectfully submitted,
Andrew M. Scharenberg, Applicant

By:


John R. Van Amsterdam, Ph.D.
Reg. No. 40,212
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: B0662.70026US00
Date: November 2, 2005
X11/20/05x